相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia
Cassandra J. Vandenberg et al.
BLOOD (2013)
Targeting BCL-2 with the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast Cancer
Francois Vaillant et al.
CANCER CELL (2013)
Bcl-2 expression predicts sensitivity to chemotherapy in breast cancer: a systematic review and meta-analysis
Dong Yang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2013)
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
Andrew J. Souers et al.
NATURE MEDICINE (2013)
Priming BCL-2 to kill: the combination therapy of tamoxifen and ABT-199 in ER+ breast cancer
Jing Deng et al.
BREAST CANCER RESEARCH (2013)
Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between triple-negative and non-triple-negative tumors
Kareem Tawfik et al.
HUMAN PATHOLOGY (2012)
Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737
Samantha R. Oakes et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Outcome of triple-negative breast cancer in patients with or without markers regulating cell cycle and cell death
Dong Won Ryu et al.
JOURNAL OF THE KOREAN SURGICAL SOCIETY (2012)
BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received
S-J Dawson et al.
BRITISH JOURNAL OF CANCER (2010)
Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer
Grace M. Callagy et al.
BMC CANCER (2008)
Clinical importance of estrogen receptor-β evaluation in breast cancer patients treated with adjuvant tamoxifen therapy
Naoko Honma et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy
Kyung-Hun Lee et al.
BMC CANCER (2007)
Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index
GM Callagy et al.
CLINICAL CANCER RESEARCH (2006)
An inhibitor of Bcl-2 family proteins induces regression of solid tumours
T Oltersdorf et al.
NATURE (2005)
The role of Bcl-2 family members in tumorigenesis
V Kirkin et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH (2004)
Antiapoptotic BCL-2 is required for maintenance of a model leukemia
A Letai et al.
CANCER CELL (2004)
Oblimersen bcl-2 antisense: Facilitating apoptosis in anticancer treatment
RJ Klasa et al.
ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT (2002)
Antimycin A mimics a cell-death-inducing Bcl-2 homology domain 3
SP Tzung et al.
NATURE CELL BIOLOGY (2001)
Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells
JL Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Evaluation of the interobserver agreement in the number of mitotic figures of breast carcinoma as simulation of quality monitoring in the Japan National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) protocol
H Tsuda et al.
JAPANESE JOURNAL OF CANCER RESEARCH (2000)
分享论文
